Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia

Nature Reviews Endocrinology

Volumn 11, Issue 1, 2015, Pages 8-9

  Mabuchi, Hiroshi ^a   Nohara, Atsushi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERINE PROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; SERINE PROTEINASE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; HUMAN; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; FEMALE; HYPERLIPOPROTEINEMIA TYPE II; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PROPROTEIN CONVERTASES;

EID: 84927175751     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.205     Document Type: Article

References (10)

1. Soutar, A. K. & Naoumova, R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4, 214-225 (2007)
2. Mabuchi, H. et al. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 236, 54-61 (2014)
3. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003)
4. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobb, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006)
5. Mabuchi, H. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478-482 (1981)
6. Brown, M. S. & Goldstein, J. L. Lowering plasma cholesterol by raising LDL receptors. N. Engl. J. Med. 305, 515-517 (1981)
7. Jacobson, T. A. et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1- executive summary. J. Clin. Lipidol. 8, 473-488 (2014)
8. Stein, E. A. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118 (2012)
9. Raal, F. J. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61399-4.
10. Raal, F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61374-X.